Pulmonary Arterial Hypertension Market is Expected to Reach $10.6 Billion by 2031 - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc

The Global Pulmonary Arterial Hypertension Market was valued at USD 7 billion in 2022 and is projected to reach USD 10.6 billion by 2031, growing at a CAGR of 5.3% from 2024 to 2031. Pulmonary arterial hypertension (PAH) is a specific form of pulmonary hypertension characterized by elevated blood pressure in the arteries of the lungs.

Pulmonary arterial hypertension (PAH) predominantly affects women aged 30-60. While a cure for PAH does not yet exist, various therapies can help alleviate symptoms and improve quality of life. PAH falls under Group 1 classification. In the United States, 500 to 1,000 new cases of PAH are diagnosed each year.

𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗣𝗗𝗙 - https://www.datamintelligence.com/download-sample/pulmonary-arterial-hypertension-market

𝗞𝗲𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀

• May 2023: The Institute for Clinical and Economic Review (ICER) will evaluate sotatercept for pulmonary arterial hypertension (PAH). This first-in-class experimental medication is designed to address abnormal signaling in pulmonary blood vessels, which contributes to PAH by causing constriction and limiting blood flow.

• May 2023: Gossamer Bio plans to initiate a Phase 3 clinical trial for seralutinib (GB002), an investigational inhaled medication for PAH. This study aims to advance towards providing a new treatment option for PAH patients.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬:

Increase in Prevalence of Pulmonary Artery Hypertension

The increasing prevalence of pulmonary arterial hypertension (PAH) is a significant driver for the market. Recent studies indicate an overall incidence of PAH at 14 cases per million, which is notably higher than the Reveal registry, with an odds ratio of 6.3 (95% CI: 4.2-9.5, p < 0.001).

Additionally, the annual period prevalence of PAH was reported as 93 cases per million, surpassing the REVEAL registry's figures, with an odds ratio of 7.5 (95% CI: 6.4-8.8). Even when focusing on patients with hemodynamic severity comparable to the REVEAL registry, the prevalence remained elevated, with an odds ratio of 3.8 (95% CI: 3.0-4.6, p < 0.001).

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀

By Drug Class: Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and Others)

By Route of Administration: Inhalation, Injectable and Oral Administration

By Distribution channel: Hospital Pharmacy, Pharmacy stores, and Others

𝗚𝗲𝘁 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗲𝗽𝗼𝗿𝘁 𝗮𝘀 𝗽𝗲𝗿 𝘆𝗼𝘂𝗿 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 - https://www.datamintelligence.com/customize/pulmonary-arterial-hypertension-market

𝗠𝗮𝗷𝗼𝗿 𝗞𝗲𝘆 𝗽𝗹𝗮𝘆𝗲𝗿𝘀

Arena Pharmaceuticals
Bayer AG
Bristol-Myers Squibb Company
Gilead Sciences Inc
GlaxoSmithKline Plc
Actelion Pharmaceuticals, Ltd. (Johnson & Johnson)
Merck & Co. Inc
Novartis International AG
Pfizer Inc
United Therapeutics Corporation

* 𝗡𝗼𝘁𝗲:

Additionally, I wanted to highlight that the full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted.

𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁𝘀:

Pulmonary Drugs Market: https://datamintelligence.com/research-report/pulmonary-drugs-market

Anti-Hypertension Drugs Market: https://datamintelligence.com/research-report/anti-hypertension-drugs-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.